Ashley Doyle
Family · Odessa, DENPI 1790226652
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 453 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 11.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,734, 7.6 times the $359 reported in 2021. Among family clinicians in DE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 453 payments — averaging $15.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$776
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$626
- Bausch Health US, LLC$564
- Novo Nordisk$561
- Alkermes, Inc.$505
- Axsome Therapeutics, Inc.$491
- plus $3K from 29 others
What the payments were for
- Food & beverage$6,892100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 39 | $776 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 56 | $626 |
| Bausch Health US, LLC | 72 | $564 |
| Novo Nordisk | 36 | $561 |
| Alkermes, Inc. | 23 | $505 |
| Axsome Therapeutics, Inc. | 28 | $491 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $429 |
| Tris Pharma Inc | 32 | $411 |
| Otsuka America Pharmaceutical, Inc. | 16 | $261 |
| Ironshore Pharmaceuticals Inc. | 14 | $209 |
| Lundbeck LLC | 10 | $191 |
| Collegium Pharmaceutical, Inc. | 14 | $187 |
| AstraZeneca | 10 | $181 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $174 |
| Lilly USA, LLC | 9 | $173 |
| Exact Sciences | 10 | $160 |
| Myovant Sciences Inc. | 1 | $116 |
| Supernus Pharmaceuticals, Inc. | 6 | $101 |
| E.r. Squibb & Sons, L.L.C. | 4 | $79 |
| Vanda Pharmaceuticals Inc. | 5 | $79 |
| Johnson & Johnson | 4 | $69 |
| GSK | 4 | $69 |
| Pfizer | 4 | $65 |
| Sage Therapeutics, LLC | 3 | $56 |
| Neurocrine Biosciences, Inc. | 3 | $55 |
| Teva Pharmaceuticals USA, Inc. | 3 | $51 |
| Idorsia Pharmaceuticals US Inc | 3 | $51 |
| Abbott | 2 | $47 |
| Corium, LLC | 3 | $39 |
| Boehringer Ingelheim | 2 | $26 |
| Biogen | 1 | $24 |
| Neos Therapeutics, LP | 1 | $21 |
| Amarin Pharma, Inc. | 1 | $17 |
| Astellas Pharma US Inc | 1 | $16 |
| Endo Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,892 in reported general payments places this provider in the 90th percentile of 523 family providers in Delaware.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 96 | $116,056 |
| FarxigaDapagliflozin Propanediol | 15 | $20,915 |
| Potassium Chloride | 11 | $1,681 |
| Atorvastatin Calcium | 55 | $755 |
| Metoprolol Succinate | 20 | $576 |
| Omeprazole | 53 | $533 |
| Rosuvastatin Calcium | 25 | $433 |
| Levothyroxine Sodium | 24 | $309 |
| Gabapentin | 18 | $305 |
| Famotidine | 21 | $262 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 11 | $239 |
| Metformin Hcl ErMetformin Hcl | 15 | $209 |
| Lisinopril | 39 | $194 |
| Dicyclomine Hcl | 12 | $157 |
| Amlodipine Besylate | 22 | $149 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $561 | $116,05696 claims |
| AstraZenecaFarxiga | $181 | $20,91515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 523 family providers in Delaware.
Other family in Odessa
- Brandi GreggeMiddletown$110K
- Tracy EstesWilmington$59K
- Kathy GallagherNewark$53K
- Jodie DelesioNewark$50K
- Abby AllenGeorgetown$43K
- Taylor HodgesLewes$33K
- Jodi KahanWilmington$21K
- Valerie HarrisonBridgeville$15K
- Kathleen GustafsonBear$15K
- Elizabeth Sharp-AsiyoWilmington$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.